A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab

Timothy Poterucha, Brian Burnette, Aminah Jatoi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Weight loss and muscle wasting are of critical importance to cancer patients because of their negative effects on survival, functional status, and tolerability of chemotherapy. Because previous data suggest vascular endothelial growth factor receptor inhibitors disrupt skeletal muscle pathways, such as PI3K and AKT, the current study explored weight loss and muscle wasting in colorectal cancer patients treated with bevacizumab. Patients were assessed for serial weight and radiographic changes in skeletal muscle at baseline and again within 3 months of starting cancer therapy. Computed tomography scans were used to assess muscle. Fifty-seven patients are the focus on this report. These patients manifested a decline in mean weight from 85 to 83 kilograms (P = 0.002). Mean skeletal muscle area at the L3 vertebral level dropped from 148 cm2 to 145 cm2 (P = 0.02). This drop in weight and skeletal muscle occurred independently of cancer progression. No statistically significant differences in survival were observed based on loss of weight or skeletal muscle. Colorectal cancer patients prescribed bevacizumab appear to lose weight and muscle over a few months even in the absence of cancer progression.

Original languageEnglish (US)
Pages (from-to)1005-1009
Number of pages5
JournalMedical Oncology
Volume29
Issue number2
DOIs
StatePublished - Jun 2012

Fingerprint

Colorectal Neoplasms
Skeletal Muscle
Weights and Measures
Drug Therapy
Muscles
Weight Loss
Neoplasms
Vascular Endothelial Growth Factor Receptor
Survival
Phosphatidylinositol 3-Kinases
Bevacizumab
Tomography
Therapeutics

Keywords

  • Bevacizumab
  • Cancer
  • Skeletal muscle
  • Wasting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. / Poterucha, Timothy; Burnette, Brian; Jatoi, Aminah.

In: Medical Oncology, Vol. 29, No. 2, 06.2012, p. 1005-1009.

Research output: Contribution to journalArticle

@article{92b688190c0e4d3ea4f9cb5a573f24a6,
title = "A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab",
abstract = "Weight loss and muscle wasting are of critical importance to cancer patients because of their negative effects on survival, functional status, and tolerability of chemotherapy. Because previous data suggest vascular endothelial growth factor receptor inhibitors disrupt skeletal muscle pathways, such as PI3K and AKT, the current study explored weight loss and muscle wasting in colorectal cancer patients treated with bevacizumab. Patients were assessed for serial weight and radiographic changes in skeletal muscle at baseline and again within 3 months of starting cancer therapy. Computed tomography scans were used to assess muscle. Fifty-seven patients are the focus on this report. These patients manifested a decline in mean weight from 85 to 83 kilograms (P = 0.002). Mean skeletal muscle area at the L3 vertebral level dropped from 148 cm2 to 145 cm2 (P = 0.02). This drop in weight and skeletal muscle occurred independently of cancer progression. No statistically significant differences in survival were observed based on loss of weight or skeletal muscle. Colorectal cancer patients prescribed bevacizumab appear to lose weight and muscle over a few months even in the absence of cancer progression.",
keywords = "Bevacizumab, Cancer, Skeletal muscle, Wasting",
author = "Timothy Poterucha and Brian Burnette and Aminah Jatoi",
year = "2012",
month = "6",
doi = "10.1007/s12032-011-9894-z",
language = "English (US)",
volume = "29",
pages = "1005--1009",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab

AU - Poterucha, Timothy

AU - Burnette, Brian

AU - Jatoi, Aminah

PY - 2012/6

Y1 - 2012/6

N2 - Weight loss and muscle wasting are of critical importance to cancer patients because of their negative effects on survival, functional status, and tolerability of chemotherapy. Because previous data suggest vascular endothelial growth factor receptor inhibitors disrupt skeletal muscle pathways, such as PI3K and AKT, the current study explored weight loss and muscle wasting in colorectal cancer patients treated with bevacizumab. Patients were assessed for serial weight and radiographic changes in skeletal muscle at baseline and again within 3 months of starting cancer therapy. Computed tomography scans were used to assess muscle. Fifty-seven patients are the focus on this report. These patients manifested a decline in mean weight from 85 to 83 kilograms (P = 0.002). Mean skeletal muscle area at the L3 vertebral level dropped from 148 cm2 to 145 cm2 (P = 0.02). This drop in weight and skeletal muscle occurred independently of cancer progression. No statistically significant differences in survival were observed based on loss of weight or skeletal muscle. Colorectal cancer patients prescribed bevacizumab appear to lose weight and muscle over a few months even in the absence of cancer progression.

AB - Weight loss and muscle wasting are of critical importance to cancer patients because of their negative effects on survival, functional status, and tolerability of chemotherapy. Because previous data suggest vascular endothelial growth factor receptor inhibitors disrupt skeletal muscle pathways, such as PI3K and AKT, the current study explored weight loss and muscle wasting in colorectal cancer patients treated with bevacizumab. Patients were assessed for serial weight and radiographic changes in skeletal muscle at baseline and again within 3 months of starting cancer therapy. Computed tomography scans were used to assess muscle. Fifty-seven patients are the focus on this report. These patients manifested a decline in mean weight from 85 to 83 kilograms (P = 0.002). Mean skeletal muscle area at the L3 vertebral level dropped from 148 cm2 to 145 cm2 (P = 0.02). This drop in weight and skeletal muscle occurred independently of cancer progression. No statistically significant differences in survival were observed based on loss of weight or skeletal muscle. Colorectal cancer patients prescribed bevacizumab appear to lose weight and muscle over a few months even in the absence of cancer progression.

KW - Bevacizumab

KW - Cancer

KW - Skeletal muscle

KW - Wasting

UR - http://www.scopus.com/inward/record.url?scp=84864629856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864629856&partnerID=8YFLogxK

U2 - 10.1007/s12032-011-9894-z

DO - 10.1007/s12032-011-9894-z

M3 - Article

C2 - 21399996

AN - SCOPUS:84864629856

VL - 29

SP - 1005

EP - 1009

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - 2

ER -